Evading anti-angiogenic therapy: Resistance to anti-angiogenic therapy in solid tumors

American Journal of Translational Research

Volumn 7, Issue 10, 2015, Pages 1675-1698

  Dey, Nandini ^a   De, Pradip ^a   Brian, Leyland Jones ^a  

^a Avera Research Institute   (United States)

Author keywords

Biomarkers; Myeloid cells; Vascular mimicry; VEGF

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; BRIVANIB; CEDIRANIB; FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 17; IRINOTECAN; NINTEDANIB; PAZOPANIB; PONATINIB; PROTEIN TYROSINE KINASE; RAMUCIRUMAB; REGORAFENIB; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BONE MARROW CELL; CLINICAL TRIAL (TOPIC); DRUG SAFETY; ENDOTHELIUM CELL; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR;

EID: 84947803699     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (144)

1. Michael S. Wolin, Ahmed M and Gupta SA. Role of Oxygen-Derived Species in the Regulation of pulmonary Vascular Tone. Springer; 2011.
2. Ide AG, Baker NH and Sl W. Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transplant ear chamber. Am J Radiol 1939; 42: 891-899.
3. Algire GH and Hw C. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 1945; 6: 73-85.
4. Ehrmann RL and Knoth M. Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy. J Natl Cancer Inst 1968; 41: 1329-1341.
5. Greenblatt M and Shubi P. Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. J Natl Cancer Inst 1968; 41: 111-124.
6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
7. Dhanabal M, Jeffers M and Larochelle WJ. Antiangiogenic therapy as a cancer treatment paradigm. Curr Med Chem Anticancer Agents 2005; 5: 115-130.
8. Gourley M and Williamson JS. Angiogenesis: new targets for the development of anticancer chemotherapies. Curr Pharm Des 2000; 6: 417-439.
9. Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 2012; 320: 130-137.
10. Azzi S, Hebda JK and Gavard J. Vascular permeability and drug delivery in cancers. Front Oncol 2013; 3: 211.
11. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
12. Auerbach R, Akhtar N, Lewis RL and Shinners BL. Angiogenesis assays: problems and pitfalls. Cancer Metastasis Rev 2000; 19: 167-172.
13. Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, Coomber BL and Rak J. Possible mechanisms of acquired resistance to antiangiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001; 20: 79-86.
14. Braga VM, Betson M, Li X and Lamarche-Vane N. Activation of the small GTPase Rac is sufficient to disrupt cadherin-dependent cell-cell adhesion in normal human keratinocytes. Mol Biol Cell 2000; 11: 3703-3721.
15. Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, Savoy DN, Molina JR, Fonseca R, Smyrk TC, Chari ST, Urrutia R and Billadeau DD. Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell 2005; 7: 39-49.
16. Mira JP, Benard V, Groffen J, Sanders LC and Knaus UG. Endogenous, hyperactive Rac3 controls proliferation of breast cancer cells by a p21-activated kinase-dependent pathway. Proc Natl Acad Sci U S A 2000; 97: 185-189.
17. Sahai E and Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002; 2: 133-142.
18. De P, Peng Q, Traktuev DO, Li W, Yoder MC, March KL and Durden DL. Expression of RAC2 in endothelial cells is required for the postnatal neovascular response. Exp Cell Res 2009; 315: 248-263.
19. Polet F and Feron O. Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force. J Intern Med 2013; 273: 156-165.
20. Schoors S, De Bock K, Cantelmo AR, Georgiadou M, Ghesquiere B, Cauwenberghs S, Kuchnio A, Wong BW, Quaegebeur A, Goveia J, Bifari F, Wang X, Blanco R, Tembuyser B, Cornelissen I, Bouche A, Vinckier S, Diaz-Moralli S, Gerhardt H, Telang S, Cascante M, Chesney J, Dewerchin M and Carmeliet P. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab 2014; 19: 37-48.
21. De Saedeleer CJ, Copetti T, Porporato PE, Verrax J, Feron O and Sonveaux P. Lactate activates HIF-1 in oxidative but not in Warburgphenotype human tumor cells. PLoS One 2012; 7: e46571.
22. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D and Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011; 91: 1071-1121.
23. Bottos A and Bardelli A. Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy? Cell Mol Life Sci 2013; 70: 4131-4140.
24. Abdollahi A and Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010; 13: 16-28.
25. Arjaans M, Oude Munnink TH, Oosting SF, Terwisscha van Scheltinga AG, Gietema JA, Garbacik ET, Timmer-Bosscha H, Lub-de Hooge MN, Schroder CP and de Vries EG. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res 2013; 73: 3347-3355.
26. Matejuk A, Collet G, Nadim M, Grillon C and Kieda C. MicroRNAs and tumor vasculature normalization: impact on anti-tumor immune response. Arch Immunol Ther Exp (Warsz) 2013; 61: 285-299.
27. Collet G, Skrzypek K, Grillon C, Matejuk A, El Hafni-Rahbi B, Lamerant-Fayel N and Kieda C. Hypoxia control to normalize pathologic angiogenesis: potential role for endothelial precursor cells and miRNAs regulation. Vascul Pharmacol 2012; 56: 252-261.
28. Vasudev NS and Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 2014; 17: 471-494.
29. Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortes J, Delmar PR and Scherer SJ. Biomarker results from the AVADO phase 3 trial of firstline bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer 2013; 108: 1052-1060.
30. Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C and Semiglazov V. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol 2013; 31: 1719-1725.
31. Ossenkoppele GJ, Stussi G, Maertens J, van Montfort K, Biemond BJ, Breems D, Ferrant A, Graux C, de Greef GE, Halkes CJ, Hoogendoorn M, Hollestein RM, Jongen-Lavrencic M, Levin MD, van de Loosdrecht AA, van Marwijk Kooij M, van Norden Y, Pabst T, Schouten HC, Vellenga E, Verhoef GE, de Weerdt O, Wijermans P, Passweg JR and Lowenberg B. Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). Blood 2012; 120: 4706-4711.
32. White D, Kassim A, Bhaskar B, Yi J, Wamstad K and Paton VE. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer 2013; 119: 339-347.
33. Fury MG, Lee NY, Sherman E, Lisa D, Kelly K, Lipson B, Carlson D, Stambuk H, Haque S, Shen R, Kraus D, Shah J and Pfister DG. A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. Cancer 2012; 118: 5008-5014.
34. Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR Jr, Chen HX, Grandis JR, Harari PM, Kies MS and Kim S. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2013; 24: 220-225.
35. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, dela Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G and Valagussa P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32.
36. Bisagni G, Musolino A, Panebianco M, De Matteis A, Nuzzo F, Ardizzoni A, Gori S, Gamucci T, Passalacqua R, Gnoni R, Moretti G and Boni C. The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. Cancer Chemother Pharmacol 2013; 71: 1051-1057.
37. Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C; Central European Cooperative Oncology Group. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol 2013; 14: 125-133.
38. Tai CJ, Chen CS, Hung CS, Kuo LJ, Wei PL, Chiou JF, Hsu CH, Chiou HY and Wu CH. Bevacizumab plus docetaxel and cisplatin for metastatic breast cancer: a pilot phase II study. Anticancer Res 2012; 32: 5501-5506.
39. Borson R, Harker G, Reeves J, Beck T, Hager S, Horvath W, Jones M, Tillinghast G, Arrowsmith E, Harrer G, Kudrik FJ, Malamud SC, Bromund J, Zeigler H, Tai DF, Kornberg LJ, Obasaju C, Orlando M and Yardley DA. Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer. Clin Breast Cancer 2012; 12: 322-330.
40. Lang I, Inbar MJ, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Messinger D, Brodowicz T and Zielinski C. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. Eur J Cancer 2012; 48: 3140-3149.
41. Kottschade LA, Suman VJ, Perez DG, McWilliams RR, Kaur JS, Amatruda TT 3rd, Geoffroy FJ, Gross HM, Cohen PA, Jaslowski AJ, Kosel ML and Markovic SN. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N0775. Cancer 2013; 119: 586-592.
42. Choo SP, Chowbay B, Ng QS, Thng CH, Lim C, Hartono S, Koh TS, Huynh H, Poon D, Ang MK, Chang S and Toh HC. A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma. Eur J Cancer 2013; 49: 999-1008.
43. Govindarajan R, Siegel E, Makhoul I and Williamson S. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma. Am J Clin Oncol 2013; 36: 254-257.
44. Hsu CH, Kang YK, Yang TS, Shun CT, Shao YY, Su WC, Sandoval-Tan J, Chiou TJ, Jin K, Hsu C and Cheng AL. Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study. Oncology 2013; 85: 44-52.
45. Yau T, Wong H, Chan P, Yao TJ, Pang R, Cheung TT, Fan ST and Poon RT. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. Invest New Drugs 2012; 30: 2384-2390.
46. Buijs M, Reyes DK, Pawlik TM, Blackford AL, Salem R, Messersmith WA, Weekes CD, Mulcahy M, Kamel IR and Geschwind JF. Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 2013; 119: 1042-1049.
47. Martin LK, Li X, Kleiber B, Ellison EC, Bloomston M, Zalupski M and Bekaii-Saab TS. VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA. Ann Oncol 2012; 23: 2812-2820.
48. Wenham RM, Lapolla J, Lin HY, Apte SM, Lancaster JM, Judson PL, Gonzalez-Bosquet J, Herschberger A, Havrilesky LJ and Secord AA. A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. Gynecol Oncol 2013; 130: 19-24.
49. Emile G, Chauvenet L, Tigaud JM, Chidiac J, Pujade Lauraine E and Alexandre J. A clinical experience of single agent bevacizumab in relapsing ovarian cancer. Gynecol Oncol 2013; 129: 459-462.
50. Ikeda Y, Takano M, Oda K, Kouta H, Goto T, Kudoh K, Sasaki N, Kita T and Kikuchi Y. Weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with recurrent and refractory ovarian cancer: a preliminary result of 19 cases. Int J Gynecol Cancer 2013; 23: 355-360.
51. Tillmanns TD, Lowe MP, Walker MS, Stepanski EJ and Schwartzberg LS. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. Gynecol Oncol 2013; 128: 221-228.
52. Verschraegen CF, Czok S, Muller CY, Boyd L, Lee SJ, Rutledge T, Blank S, Pothuri B, Eberhardt S and Muggia F. Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum-and taxane-resistant ovarian cancer. Ann Oncol 2012; 23: 3104-3110.
53. Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME and Oh WK. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer 2012; 118: 4777-4784.
54. Loupakis F, Schirripa M, Caparello C, Funel N, Pollina L, Vasile E, Cremolini C, Salvatore L, Morvillo M, Antoniotti C, Marmorino F, Masi G and Falcone A. Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. Br J Cancer 2013; 108: 2549-2556.
55. Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM and Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid heman gioendotheliomas. Ann Oncol 2013; 24: 257-263.
56. Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J and Kurzrock R. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res 2012; 18: 5796-5805.
57. Okines AF, Langley RE, Thompson LC, Stenning SP, Stevenson L, Falk S, Seymour M, Coxon F, Middleton GW, Smith D, Evans L, Slater S, Waters J, Ford D, Hall M, Iveson TJ, Petty RD, Plummer C, Allum WH, Blazeby JM, Griffin M and Cunningham D. Bevacizumab with perioperative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Ann Oncol 2013; 24: 702-709.
58. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D and Carbone DP. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096-1103.
59. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, Friedlander P, Flaherty KT, Murphy GF, Rodig S, Velazquez EF, Mihm MC, Jr, Russell S, DiPiro PJ, Yap JT, Ramaiya N, Van den Abbeele AD, Gargano M and McDermott D. Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma. Cancer Immunol Res 2014; 2: 632-642.
60. Konigsberg R, Maierhofer J, Steininger T, Kienzer G and Dittrich C. Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab. Radiol Oncol 2014; 48: 184-188.
61. Gaykema SB, Brouwers AH, Lub-de Hooge MN, Pleijhuis RG, Timmer-Bosscha H, Pot L, van Dam GM, van der Meulen SB, de Jong JR, Bart J, de Vries J, Jansen L, de Vries EG and Schroder CP. 89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med 2013; 54: 1014-1018.
62. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O’Neill V and Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011; 29: 4286-4293.
63. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC and O’Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011; 29: 1252-1260.
64. Liu S and Kurzrock R. Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. Cancer Treat Rev 2014; 40: 883-891.
65. Bécouarn Y, Cany L, Pulido M, Beyssac R, Texereau P, Le Morvan V, Béchade D, Brunet R, Aitouferoukh S, Lalet C, Mathoulin-Pélissier S, Fonck M, Robert J. FOLFIRI(R) and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms. BMC Res Notes 2014; 7: 260.
66. Verheul HM and Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7: 475-485.
67. Saif MW. Managing bevacizumab-related toxicities in patients with colorectal cancer. J Support Oncol 2009; 7: 245-251.
68. Torino F, Corsello SM, Longo R, Barnabei A and Gasparini G. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009; 6: 219-228.
69. Boehm S, Rothermundt C, Hess D and Joerger M. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly-a mini-review. Gerontology 2010; 56: 303-309.
70. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF and Hawkins RE. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068.
71. Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Maelandsmo GM and Engebraaten O. Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations. Clin Cancer Res 2014; 20: 404-412.
72. Durm G and Hanna N. Targeting multiple angiogenic pathways simultaneously: experience with nintedanib in non-small-cell lung cancer. Future Oncol 2014; 10: 1167-1173.
73. Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff PW, Garraway LA and Rosenberg JE. Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib. Cancer Discov 2014; 4: 546-553.
74. Jain RK, Duda DG, Clark JW and Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3: 24-40.
75. Krupitskaya Y and Wakelee HA. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs 2009; 10: 597-605.
76. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J and Investigators RT. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-39.
77. Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent FW, Duda DG and Stuart K. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as firstline monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res 2013; 19: 6614-6623.
78. Garon EB, Cao D, Alexandris E, John WJ, Yurasov S and Perol M. A randomized, doubleblind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design. Clin Lung Cancer 2012; 13: 505-509.
79. Loges S, Schmidt T and Carmeliet P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 2010; 1: 12-25.
80. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 2013; 31: 2205-2218.
81. Ribatti D, Vacca A and Dammacco F. The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1999; 1: 293-302.
82. Folkman J. Tumor angiogenesis. Philadelphia: WB Saunders; 1995.
83. Folkman J. Angiogenesis. Amsterdam: Martinus Nijhoff Publishing; 1984.
84. Hanahan D and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
85. Ribatti D, Vacca A and Dammacco F. New nonangiogenesis dependent pathways for tumour growth. Eur J Cancer 2003; 39: 1835-1841.
86. Pezzella F, Pastorino U, Tagliabue E, Andreola S, Sozzi G, Gasparini G, Menard S, Gatter KC, Harris AL, Fox S, Buyse M, Pilotti S, Pierotti M and Rilke F. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 1997; 151: 1417-1423.
87. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD and Wiegand SJ. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-1998.
88. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ and Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
89. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe’er J, Trent JM, Meltzer PS and Hendrix MJ. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155: 739-752.
90. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R and Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194-1201.
91. Clarijs R, Ruiter DJ and de Waal RM. Lymphangiogenesis in malignant tumours: Does it occur? J Pathol 2001; 193: 143-146.
92. Stacker SA, Baldwin ME and Achen MG. The role of tumor lymphangiogenesis in metastatic spread. FASEB J 2002; 16: 922-934.
93. Yao XH, Ping YF and Bian XW. Contribution of cancer stem cells to tumor vasculogenic mimicry. Protein Cell 2011; 2: 266-272.
94. Liu TJ, Sun BC, Zhao XL, Zhao XM, Sun T, Gu Q, Yao Z, Dong XY, Zhao N and Liu N. CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triplenegative breast cancer. Oncogene 2013; 32: 544-553.
95. Ping YF and Bian XW. Consice review: Contribution of cancer stem cells to neovascularization. Stem Cells 2011; 29: 888-894.
96. Fox SB, Generali DG and Harris AL. Breast tumour angiogenesis. Breast Cancer Res 2007; 9: 216.
97. Tong M, Han BB, Holpuch AS, Pei P, He L and Mallery SR. Inherent phenotypic plasticity fa cilitates progression of head and neck cancer: endotheliod characteristics enable angiogenesis and invasion. Exp Cell Res 2013; 319: 1028-1042.
98. Shih IeM. Trophoblastic vasculogenic mimicry in gestational choriocarcinoma. Mod Pathol 2011; 24: 646-652.
99. Shirakawa K, Kobayashi H, Sobajima J, Hashimoto D, Shimizu A and Wakasugi H. Inflammatory breast cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model. Breast Cancer Res 2003; 5: 136-139.
100. Guzman G, Cotler SJ, Lin AY, Maniotis AJ and Folberg R. A pilot study of vasculogenic mimicry immunohistochemical expression in hepatocellular carcinoma. Arch Pathol Lab Med 2007; 131: 1776-1781.
101. Sood AK, Seftor EA, Fletcher MS, Gardner LM, Heidger PM, Buller RE, Seftor RE and Hendrix MJ. Molecular determinants of ovarian cancer plasticity. Am J Pathol 2001; 158: 1279-1288.
102. Yao X, Ping Y, Liu Y, Chen K, Yoshimura T, Liu M, Gong W, Chen C, Niu Q, Guo D, Zhang X, Wang JM and Bian X. Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a key role in vasculogenic mimicry formation, neovascularization and tumor initiation by Glioma stemlike cells. PLoS One 2013; 8: e57188.
103. Itzhaki O, Greenberg E, Shalmon B, Kubi A, Treves AJ, Shapira-Frommer R, Avivi C, Ortenberg R, Ben-Ami E, Schachter J, Besser MJ and Markel G. Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma. PLoS One 2013; 8: e57160.
104. Soda Y, Myskiw C, Rommel A and Verma IM. Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. J Mol Med (Berl) 2013; 91: 439-448.
105. Paulis YW, Soetekouw PM, Verheul HM, Tjan-Heijnen VC and Griffioen AW. Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta 2010; 1806: 18-28.
106. Basu GD, Liang WS, Stephan DA, Wegener LT, Conley CR, Pockaj BA and Mukherjee P. A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast Cancer Res 2006; 8: R69.
107. Shirakawa K, Shibuya M, Heike Y, Takashima S, Watanabe I, Konishi F, Kasumi F, Goldman CK, Thomas KA, Bett A, Terada M and Wakasugi H. Tumor-infiltrating endothelial cells and endothelial precursor cells in inflammatory breast cancer. Int J Cancer 2002; 99: 344-351.
108. Liu T, Sun B, Zhao X, Gu Q, Dong X, Yao Z, Zhao N, Chi J, Liu N, Sun R and Ma Y. HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinoma. J Cell Mol Med 2013; 17: 116-122.
109. Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, Saito K and Konishi F. Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer 2002; 99: 821-828.
110. Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M, Sasaki H, Kasumi F, Yoshimoto M, Iwanaga T, Konishi F, Terada M and Wakasugi H. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 2001; 61: 445-451.
111. Pezzella FP, Manzotti M, Bacco AD, Viale G, Nicholson AG, Richard Price, Cathy Ratcliffe, Ugo Pastorino, Kevin C Gatter, Adrian L Harris, Douglas G Altman, Silvana Pilotti and Veronesi U. Evidence for novel non-angiogenic pathway in breast-cancer metastasis. Breast Cancer Progression Working Party. Lancet 2000; 355: 1787-1788.
112. De P, Carlson J, Leyland-Jones B and Dey N. Wnt-b-Catenin Pathway Regulates Vascular Mimicry in Triple Negative Breast Cancer. Journal of Cytology & Histology 2013; [Epub ahead of print].
113. Dey N, Barwick B, Moreno C, Ordanic-Kodani M, Chen Z, De P, Tang W, Catzavelos C, Kerstann K, Sledge GW, Abramovitz M, Bouzyk M and Leyland-Jones B. Wnt Signaling in Triple Negative Breast Cancer is Associated with Poor Prognosis and Metastasis. BMC Cancer 2013; 13: 537.
114. Dey N, Young B, Abramovitz M, Bouzyk M, Barwick B, De P and Leyland-Jones B. Differential Activation of Wnt-b-Catenin Pathway in Triple Negative Breast Cancer Increases MMP7 in a PTEN Dependent Manner. PLos One 2013; 8: e77425.
115. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK and Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A 2000; 97: 14608-14613.
116. Ferrara N. Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis. Curr Opin Hematol 2010; 17: 219-224.
117. Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2009; 29: 789-791.
118. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT and Sorensen AG. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009; 6: 327-338.
119. Ferrara N. Pathways mediating VEGFindependent tumor angiogenesis. Cytokine Growth Factor Rev 2010; 21: 21-26.
120. Holmes K, Roberts OL, Thomas AM and Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007; 19: 2003-2012.
121. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G and Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967.
122. Li Calzi S, Neu MB, Shaw LC, Kielczewski JL, Moldovan NI and Grant MB. EPCs and pathological angiogenesis: when good cells go bad. Microvasc Res 2010; 79: 207-216.
123. Pohl M, Werner N, Munding J, Tannapfel A, Graeven U, Nickenig G, Schmiegel W and Reinacher-Schick A. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature. Z Gastroenterol 2011; 49: 1398-1406.
124. Jahangiri A and Aghi MK. Biomarkers predicting tumor response and evasion to anti-angiogenic therapy. Biochim Biophys Acta 2012; 1825: 86-100.
125. Crawford Y and Ferrara N. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol Sci 2009; 30: 624-630.
126. Shojaei F and Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/ resistance to anti-angiogenic therapies. Drug Resist Updat 2008; 11: 219-230.
127. Ricard C, Stanchi F, Rodriguez T, Amoureux MC, Rougon G and Debarbieux F. Dynamic Quantitative Intravital Imaging of Glioblastoma Progression Reveals a Lack of Correlation between Tumor Growth and Blood Vessel Density. PLoS One 2013; 8: e72655.
128. Duda DG, Ancukiewicz M and Jain RK. Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers? J Clin Oncol 2010; 28: 183-185.
129. Hayashi H, Arao T, Matsumoto K, Kimura H, Togashi Y, Hirashima Y, Horita Y, Iwasa S, Okita NT, Honma Y, Takashima A, Kato K, Hamaguchi T, Shimada Y, Nakagawa K, Nishio K and Yamada Y. Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma. Oncotarget 2014; 5: 2588-2595.
130. Bousquet G and Janin A. Reactive resistance to anti-angiogenic drugs. Aging (Albany NY) 2015; 7: 282-283.
131. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ and Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A 2007; 104: 17069-17074.
132. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S and Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 820-827.
133. Dey N, Leyland-Jones B and De P. Evolution of Tumor Model: From Animal Model of Tumor to Tumor Model in Animal. Journal of Cancer Therapy 2013; 4: 1411-1425.
134. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP and Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007; 25: 911-920.
135. Mollay C, Wechselberger C, Mignogna G, Negri L, Melchiorri P, Barra D and Kreil G. Bv8, a small protein from frog skin and its homologue from snake venom induce hyperalgesia in rats. Eur J Pharmacol 1999; 374: 189-196.
136. Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, Blanchard D, Bais C, Peale FV, van Bruggen N, Ho C, Ross J, Tan M, Carano RA, Meng YG and Ferrara N. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007; 450: 825-831.
137. Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, Meng YG and Ferrara N. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A 2009; 106: 6742-6747.
138. Zhong C, Qu X, Tan M, Meng YG and Ferrara N. Characterization and regulation of bv8 in human blood cells. Clin Cancer Res 2009; 15: 2675-2684.
139. Granger JM and Kontoyiannis DP. Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study. Cancer 2009; 115: 3919-3923.
140. Perez FA, Fligner CL and Yu EY. Rapid clinical deterioration and leukemoid reaction after treatment of urothelial carcinoma of the bladder: possible effect of granulocyte colony-stimulating factor. J Clin Oncol 2009; 27: e215-e217.
141. Hermann PC, Trabulo SM, Sainz B Jr, Balic A, Garcia E, Hahn SA, Vandana M, Sahoo SK, Tunici P, Bakker A, Hidalgo M and Heeschen C. Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. PLoS One 2013; 8: e66371.
142. Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, Vernes JM, Jiang Z, Meng YG, Peale FV, Ouyang W and Ferrara N. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med 2013; 19: 1114-1123.
143. Francia G, Emmenegger U and Kerbel RS. Tumor-associated fibroblasts as “Trojan Horse” mediators of resistance to anti-VEGF therapy. Cancer Cell 2009; 15: 3-5.
144. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, Kaminker J and Ferrara N. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009; 15: 21-34.